Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Willett
Christopher G
CG
Boucher
Yves
Y
Duda
Dan G
DG
di Tomaso
Emmanuelle
E
Munn
Lance L
LL
Tong
Ricky T
RT
Kozin
Sergey V
SV
Petit
Lucine
L
Jain
Rakesh K
RK
Chung
Daniel C
DC
Sahani
Dushyant V
DV
Kalva
Sanjeeva P
SP
Cohen
Kenneth S
KS
Scadden
David T
DT
Fischman
Alan J
AJ
Clark
Jeffrey W
JW
Ryan
David P
DP
Zhu
Andrew X
AX
Blaszkowsky
Lawrence S
LS
Shellito
Paul C
PC
Mino-Kenudson
Mari
M
Lauwers
Gregory Y
GY
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015415:Biomarkers; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000068258:Bevacizumab; D005472:Fluorouracil